Ambitious Plan to Screen for Endocrine Disruptors Unveiled

A proposed plan to screen about 15,000 commercial chemicals that may interact harmfully with the endocrine system could be one of the most ambitious and expensive such efforts ever. The first tier of the two-part plan would cost an estimated $200,000 per chemical for high throughput screening. Those screens would test chemicals for interactions with five endocrine receptors, including estrogen, androgen, and thyroid receptors. Chemicals testing positive would move on to the next level, which co

Written byPaul Smaglik
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

A proposed plan to screen about 15,000 commercial chemicals that may interact harmfully with the endocrine system could be one of the most ambitious and expensive such efforts ever. The first tier of the two-part plan would cost an estimated $200,000 per chemical for high throughput screening. Those screens would test chemicals for interactions with five endocrine receptors, including estrogen, androgen, and thyroid receptors. Chemicals testing positive would move on to the next level, which could cost up to $2 million apiece. Chemicals in that level would be tested in a variety of animal models for damage to reproduction and development.

A group of 39 scientists from government, academia, and industry drafted the plan, which was presented at the American Chemical Society's annual meeting in Boston last month. The Endocrine Disrupter Screening and Testing Advisory Committee (EDSTAC) was formed after 1996 amendments to the Food Quality Protection Act and Safe ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies